Study guide
16.5 Psychotropic Pharmacology & Cardiac Safety
AACVPR CCRP Certified Cardiac Rehab Professional Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Cardiac Rehabilitation Foundations
1.1 AACVPR CCRP Credential, Exam Specifications & Core Competencies 1.2 Phases of Cardiac Rehabilitation & Clinical Delivery Models 1.3 Interdisciplinary Team Roles, Clinical Scope of Practice & Safety
2 Chapter 2: Cardiovascular Anatomy, Physiology & Pathology
2.1 Cardiac Anatomy, Coronary Circulation & Hemodynamics 2.2 Atherosclerosis Pathogenesis, Acute Coronary Syndromes (ACS) & Revascularization 2.3 Heart Failure (HFrEF/HFpEF), Cardiomyopathies & Valvular Heart Disease 2.4 Electrical Interventions: Cardioversion, Catheter Ablation & Post-Procedure Rehabilitation
3 Chapter 3: Diagnostic Evaluation, ECG & Clinical Testing
3.1 Baseline Clinical Assessment & AACVPR Risk Stratification 3.2 12-Lead ECG Interpretation: Ischemia, Transmural Infarction & Conduction 3.3 Cardiac Arrhythmias, Conduction Blocks & Device Rhythms (Pacemakers/ICDs) 3.4 Graded Exercise Testing (GXT), Gas Exchange & Termination Criteria
4 Chapter 4: Patient-Centered Assessment: Education, Equity & Social Context
4.1 Learning Readiness: Health Literacy, Learning Styles & Communication Barriers 4.2 Social Determinants of Health, Culture & Spirituality in Cardiac Rehab 4.3 Sex- and Race-Based Differences in Cardiovascular Presentation & Outcomes 4.4 Substance Use Screening: Alcohol, Cannabis, Stimulants & Cardiac Risk
5 Chapter 5: Exercise Prescription & Aerobic Conditioning
5.1 FITT-VP Framework & Aerobic Exercise Intensity Calculation 5.2 Exercise Progression, Environmental Factors & Telemetry Monitoring Guidelines 5.3 High-Intensity Interval Training (HIIT) vs Moderate Continuous Training (MICT) 5.4 Home Exercise Program Design, Prescription & Independent Progression
6 Chapter 6: Exercise Physiology, Monitoring & Session Design
6.1 Health-Related Physical Fitness Components & Functional Capacity Testing 6.2 Acute Cardiovascular Responses to Aerobic Exercise: METs, Rate Pressure Product & VO₂ 6.3 Chronic Training Adaptations in Cardiac Patients 6.4 Structuring the Exercise Session: Warm-Up, Conditioning & Cool-Down 6.5 ECG Telemetry Setup: Skin Preparation, Electrode Placement & Artifact Troubleshooting 6.6 Pulse Oximetry, Exertional Desaturation & Supplemental Oxygen Titration
7 Chapter 7: Resistance, Flexibility & Exercise Safety
7.1 Resistance Training Guidelines, Hemodynamics & Sternal Precautions 7.2 Flexibility, Neuromotor Training & Special CR Populations 7.3 Exercise Contraindications, Adverse Signs/Symptoms & Emergency Protocols
8 Chapter 8: Physical Activity Counseling & Behavior Change
8.1 Physical Activity Guidelines, Sedentary Physiology & NEAT 8.2 Behavioral Change Theories: Transtheoretical Model & Social Cognitive Theory 8.3 Motivational Interviewing Principles & Resolving Ambivalence 8.4 SMART Goal Setting, Activity Tracking & Relapse Prevention
9 Chapter 9: Physical Activity Assessment & Real-World Activity Counseling
9.1 Physical Activity vs Exercise: Assessment Instruments, Logs & Wearables 9.2 Metabolic Requirements of Daily Life: Occupational, Recreational & Sexual Activity 9.3 Environmental & Situational Risk: Heat, Cold, Altitude, Air Quality & High-Risk Activities 9.4 Upper- vs Lower-Body Physiologic Demands & Modality Selection
10 Chapter 10: Hypertension & Blood Pressure Regulation
10.1 2017 ACC/AHA Hypertension Classification & Cardiovascular Risk 10.2 Antihypertensive Pharmacology & Exercise Hemodynamics 10.3 Exertional Blood Pressure Dynamics, Exertional Hypotension & Crisis 10.4 Home Blood Pressure Monitoring, Sodium Restriction & Lifestyle Interventions 10.5 Blood Pressure Measurement Technique, Device Validation & Renal Protection
11 Chapter 11: Diabetes Mellitus & Metabolic Regulation
11.1 Diabetes Pathophysiology, Diagnostic Criteria & Glycemic Targets 11.2 Antidiabetic Pharmacotherapy (Insulin, Sulfonylureas, SGLT2i, GLP-1 RA) 11.3 Exercise-Induced Hypoglycemia Management (Rule of 15) & Hyperglycemia 11.4 Diabetic Complications & Exercise Adaptations (Autonomic & Peripheral Neuropathy) 11.5 Blood Glucose Self-Monitoring, CGM Interpretation & Peri-Exercise Testing 11.6 Diabetic Foot Care, Skin Integrity & Footwear Assessment
12 Chapter 12: Blood Lipid Management & Atherosclerosis Prevention
12.1 Lipid Metabolism, Atherogenic Lipoproteins & Advanced Lipid Testing 12.2 Statin Therapy, Dosing Intensity & Secondary Prevention Targets 12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)
13 Chapter 13: Medical Nutrition Therapy & Dietary Patterns
13.1 Nutritional Assessment & Macronutrient Guidelines in Cardiovascular Disease 13.2 Cardioprotective Dietary Patterns: Mediterranean, DASH & Plant-Based 13.3 Dietary Lipids, Sodium, Soluble Fiber & Plant Stanols/Sterols 13.4 Clinical Scope: CR Professional Counseling Boundaries vs RD/RDN Referral
14 Chapter 14: Body Composition & Weight Management
14.1 Anthropometric Assessment: BMI, Waist Circumference & Obesity Paradox 14.2 Behavioral Weight Management, Energy Balance & Caloric Deficits 14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations
15 Chapter 15: Tobacco Cessation Interventions
15.1 Cardiovascular Pathophysiology of Tobacco, Nicotine & Secondhand Smoke 15.2 Clinical Cessation Frameworks: The 5 A's & 5 R's Models 15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion 15.4 Behavioral Counseling, Coping Strategies & Relapse Prevention
16 Chapter 16: Psychosocial Health, Screening & Behavioral Support
16.1 Psychosocial Risk Factors & Prognostic Impact in Heart Disease 16.2 Validated Screening Instruments: PHQ-9, GAD-7 & Administration 16.3 Evidence-Based Interventions: Stress Management, CBT Principles & Social Support 16.4 Crisis Protocols, Suicidal Ideation & Mental Health Referral Pathways 16.5 Psychotropic Pharmacology & Cardiac Safety 16.6 Sleep Disturbance, Chronic Pain & Somatic Comorbidity in Psychosocial Management
17 Chapter 17: Regulatory Compliance, Documentation & Program Outcomes
17.1 CMS Coverage Guidelines, Qualifying Diagnoses & Practitioner Supervision 17.2 Individualized Treatment Plan (ITP) Components, 30-Day Updates & Goals 17.3 AACVPR Outcome Domains & Program Certification Performance Measures 17.4 Program Certification, Quality Improvement & Medical Emergency Preparedness
16.5 Psychotropic Pharmacology & Cardiac Safety
Key Takeaways Explain This Topic AI
Sertraline is the best-studied antidepressant in post-myocardial-infarction patients and, with escitalopram, is generally preferred for cardiac safety.
Citalopram carries dose-dependent QT prolongation, with the FDA limiting the dose to 20 mg daily in adults over 60 and in hepatic impairment or CYP2C19 poor metabolizers.
SSRIs impair platelet serotonin uptake and increase bleeding risk, which is clinically relevant in patients on dual antiplatelet therapy or anticoagulants.
Tricyclic antidepressants cause orthostatic hypotension, anticholinergic effects, and QT prolongation with proarrhythmic potential, and are generally avoided after myocardial infarction.
Antidepressants require 4 to 6 weeks for full effect and should never be stopped abruptly; paroxetine and venlafaxine in particular produce a marked discontinuation syndrome.
Last updated: September 2026
16.5 Psychotropic Pharmacology & Cardiac Safety
Note
Blueprint anchors : Domain 8 (Psychosocial Management), task 8.5 — Identify psychosocial medications and their common side effects ; and task 8.10 — Reinforce the importance of psychosocial medication adherence .
Depression affects roughly one in five patients after myocardial infarction and independently predicts mortality, so many CR participants are taking psychotropic medication. These drugs interact with cardiac medications, alter heart rate and blood pressure responses to exercise, and affect bleeding risk and QT interval. The CR professional does not prescribe or adjust them — but is often the clinician who sees the patient most frequently and is best positioned to recognize a problem and reinforce adherence.
SSRIs: The First-Line Class
Selective serotonin reuptake inhibitors are first-line for depression in cardiac patients.
- Agent Cardiac considerations
- Sertraline Best-studied in post-MI patients; favorable cardiac safety profile; commonly preferred
- Escitalopram Also generally preferred; well tolerated
Citalopram Dose-dependent QT prolongation. FDA limits the dose to 20 mg/day in adults over 60 , in hepatic impairment, and in CYP2C19 poor metabolizers or with concurrent CYP2C19 inhibitors
- Fluoxetine Long half-life; potent CYP2D6 inhibitor
- Paroxetine Potent CYP2D6 inhibitor ; most anticholinergic of the SSRIs; marked discontinuation syndrome
- Class effects to recognize
Bleeding risk : SSRIs block platelet serotonin uptake, impairing platelet aggregation. Combined with aspirin plus a P2Y12 inhibitor or with an anticoagulant, this meaningfully raises bleeding risk. Watch for bruising, gingival bleeding, epistaxis, and GI bleeding, and report them.
Hyponatremia (SIADH) , particularly in older adults and with concurrent diuretics — presents as confusion, weakness, falls, or seizures.
GI upset, sexual dysfunction, initial anxiety or activation , sleep disturbance.
Serotonin syndrome with serotonergic combinations — agitation, hyperreflexia, clonus, hyperthermia, autonomic instability.
Warning
CYP2D6 interaction with metoprolol. Fluoxetine and paroxetine potently inhibit CYP2D6, the enzyme that metabolizes metoprolol . Co-prescription raises metoprolol levels and can produce bradycardia, fatigue, hypotension, and a further blunted heart rate response to exercise . A CR patient who becomes unusually bradycardic or exercise-intolerant after starting one of these SSRIs should have the interaction flagged to the prescriber. Carvedilol is also a CYP2D6 substrate.
Other Antidepressant Classes
Class / agent Key cardiac-relevant effects
SNRIs (venlafaxine, duloxetine) Dose-dependent blood pressure elevation — monitor BP, particularly at higher venlafaxine doses; also useful for neuropathic pain (duloxetine)
Tricyclics (amitriptyline, nortriptyline) Orthostatic hypotension , anticholinergic effects (dry mouth, urinary retention, constipation, confusion), QT prolongation and proarrhythmia ; generally avoided post-MI ; amitriptyline is frequently prescribed at low dose for neuropathic pain or insomnia, so ask specifically
Bupropion No sexual dysfunction, weight-neutral or reducing; also first-line for smoking cessation ; lowers seizure threshold (contraindicated with seizure disorder, bulimia, anorexia); can raise blood pressure
Mirtazapine Sedation and appetite stimulation with weight gain — sometimes deliberately chosen for the underweight, poorly sleeping patient; orthostatic hypotension
- Trazodone Widely used at low dose for insomnia; orthostatic hypotension , sedation, rare priapism
- Anxiolytics, Antipsychotics, and Mood Stabilizers
- Benzodiazepines
Effective acutely but problematic chronically: sedation, impaired balance and falls, cognitive impairment, tolerance, and dependence , with a difficult and potentially dangerous withdrawal. They appear on the Beers criteria as potentially inappropriate in older adults. In a CR gym, a benzodiazepine-sedated patient is a fall risk on a treadmill. Never advise abrupt discontinuation — refer to the prescriber for a taper.
Antipsychotics
QT prolongation (notably with ziprasidone, haloperidol, and others) and metabolic effects — weight gain, dyslipidemia, insulin resistance, and new-onset diabetes, especially with olanzapine and clozapine. These directly worsen the cardiovascular risk profile CR is trying to improve, so weight, lipids, and glucose deserve closer monitoring in patients taking them.
Lithium
Narrow therapeutic index. Levels rise with dehydration, sodium depletion, thiazide diuretics, NSAIDs, and ACE inhibitors or ARBs — a combination that is common in cardiac patients and directly relevant to exercise-related fluid loss. Toxicity presents as tremor, ataxia, confusion, vomiting, and arrhythmia. Counsel on consistent hydration and sodium intake, and flag heat exposure and heavy sweating to the prescriber.
Adherence: The CR Professional's Main Lever
Adherence to antidepressants is poor, and the reasons are predictable and addressable:
Barrier Counseling response
"It isn't working" at 1-2 weeks Antidepressants require 4 to 6 weeks for full effect; some improvement in sleep and appetite precedes mood change
"I feel better, so I stopped" Feeling better means the medication is working; continuation for months after remission is standard to prevent relapse
Side effects early Nausea, headache, and activation often attenuate over 1 to 2 weeks; report persistent effects to the prescriber rather than stopping
Stigma Normalize: depression after a cardiac event is common and independently affects survival; treating it is cardiac care
- Cost Screen for cost-related non-adherence; most SSRIs are inexpensive generics
- Polypharmacy burden Simplify timing where possible; use pill organizers
Warning
Never advise a patient to stop a psychotropic abruptly. SSRI and SNRI discontinuation syndrome — dizziness, "brain zaps," flu-like symptoms, irritability, insomnia — is particularly pronounced with paroxetine and venlafaxine due to short half-lives. Abrupt benzodiazepine withdrawal can cause seizures. Any change belongs to the prescriber.
Scope boundary
Important
The CR professional's role is to recognize, monitor, report, and reinforce — not to prescribe, adjust, or discontinue. Monitor orthostatic vital signs, heart rate response during exercise, bleeding signs, sedation and fall risk, and weight and glucose trends; report changes to the prescriber; and reinforce adherence with accurate information about onset and duration of therapy.
Realistic Clinical Scenario
Scenario : A 59-year-old woman 6 weeks post-MI is on aspirin, ticagrelor, metoprolol, atorvastatin, and lisinopril. Her PHQ-9 was 16 at intake, and her primary care physician started paroxetine 20 mg two weeks ago. She now reports fatigue, and her resting heart rate has fallen from 68 to 52 bpm with a markedly blunted rate response during exercise. She has new gum bleeding when brushing. She tells you she is going to stop the paroxetine because "it's making me tired and it isn't helping anyway."
Analysis : Three distinct issues converge. First, paroxetine is a potent CYP2D6 inhibitor and metoprolol is a CYP2D6 substrate — the new bradycardia, fatigue, and blunted exercise heart rate response are highly consistent with elevated metoprolol levels from this interaction. Second, the gum bleeding reflects the additive bleeding risk of an SSRI on top of dual antiplatelet therapy with aspirin and ticagrelor. Third, at two weeks she is inside the normal 4-to-6-week window before full antidepressant effect, so "it isn't helping" is an expectation problem, not a treatment failure — and paroxetine has one of the most pronounced discontinuation syndromes, so stopping abruptly would be actively harmful.
Plan : Advise her explicitly not to stop the medication on her own and explain why — both that the benefit takes 4 to 6 weeks and that abrupt paroxetine cessation causes withdrawal symptoms. Contact the prescriber the same day to report the suspected CYP2D6 interaction with metoprolol, the bradycardia and blunted exercise response with specific heart rate values, and the new bleeding, noting that an alternative SSRI such as sertraline or escitalopram avoids the CYP2D6 issue — but leave the decision to the prescriber. Meanwhile, prescribe exercise intensity by RPE and the talk test rather than heart rate given her unreliable chronotropic response, monitor orthostatic vital signs, and document the bleeding. Re-administer the PHQ-9 at the 30-day update to track response objectively.